Amanote Research
Register
Sign In
Medicare Is Likely to Pay for Anticancer Drugs
BMJ
doi 10.1136/bmj.324.7346.1118/b
Full Text
Open PDF
Abstract
Available in
full text
Date
May 11, 2002
Authors
F. Charatan
Publisher
BMJ
Related search
Care Patterns in Medicare and Their Implications for Pay for Performance
New England Journal of Medicine
Medicine
Medicare Part D Payments for Neurologist-Prescribed Drugs
Neurology
Neurology
Is Radioiodine More Likely Than Antithyroid Drugs to Worsen Ophthalmopathy in Patients With Graves Disease?
Nature Clinical Practice Endocrinology & Metabolism
Metabolic Monosaccharides Altered Cell Responses to Anticancer Drugs
European Journal of Pharmaceutics and Biopharmaceutics
Medicine
Biotechnology
Pharmaceutical Science
Pricing in the Market for Anticancer Drugs
Structural Basis for Smoothened Receptor Modulation and Chemoresistance to Anticancer Drugs
Nature Communications
Astronomy
Genetics
Molecular Biology
Biochemistry
Chemistry
Physics
Dendrimers for Drug Delivery of Anticancer Drugs
KLHL5 Knockdown Increases Cellular Sensitivity to Anticancer Drugs
Oncotarget
Oncology
Pay-For-Performance or Compliance? A Second Opinion on Medicare Reimbursement
Indiana Health Law Review